outbreak
sar
warrant
search
antivir
compound
treat
diseas
present
specif
treatment
identifi
sarsassoci
coronaviru
infect
assess
antivir
potenti
ribavirin
pyrazofurin
mycophenol
acid
glycyrrhizin
two
clinic
isol
coronaviru
patient
sar
admit
clinic
centr
frankfurt
univers
germani
compound
glycyrrhizin
activ
inhibit
replic
sarsassoci
viru
find
suggest
glycyrrhizin
assess
treatment
sar
new
coronaviru
identifi
patient
sever
acut
respiratori
syndrom
sar
sar
infecti
diseas
high
potenti
transmiss
close
contact
outbreak
sar
sever
countri
led
search
activ
antivir
compound
treat
diseas
assess
antivir
activ
ribavirin
pyrazofurin
mycophenol
acid
glycyrrhizin
two
clinic
isol
coronaviru
patient
sar
admit
clinic
centr
frankfurt
univers
germani
compound
avail
commerci
use
patient
antivir
antitumour
immunosuppress
activ
visual
score
cytopathogen
induc
viru
h
infect
micropl
confluent
layer
vero
cell
select
index
determin
ratio
concentr
compound
reduc
cell
viabil
cc
concentr
compound
need
inhibit
cytopath
effect
control
valu
ec
determin
cytotox
drug
mmt
cellprolif
kit
roch
mannheim
germani
ribavirin
mycophenol
acid
inhibitor
inosin
monophosph
dehydrogenas
affect
replic
sarsassoci
coronavirus
sarscv
tabl
inhibitor
orotidin
monophosph
decarboxylas
pyrazofurin
inhibit
replic
sarscv
nontox
dose
select
indic
respect
potent
inhibitor
sarscv
replic
vero
cell
glycyrrhizin
select
index
addit
inhibit
viru
replic
glycyrrhizin
inhibit
adsorpt
penetr
virusearli
step
replic
cycl
glycyrrhizin
less
effect
ad
adsorpt
period
ad
viru
adsorpt
ec
mgl
vs
mgl
respect
glycyrrhizin
effect
given
adsorpt
period
ec
mgl
figur
show
effect
glycyrrhizin
replic
sarscv
vero
cell
detect
replic
sarscv
serum
sampl
patient
sar
express
viral
antigen
much
lower
cultur
treat
mgl
glycyrrhizin
half
elderli
peopl
degre
cerebr
white
matter
lesion
howev
rate
progress
lesion
uncertain
aim
assess
progress
lesion
communitydwel
volunt
age
year
without
neuropsychiatr
diseas
use
mri
grade
measur
total
volum
white
matter
lesion
volunt
baselin
year
year
particip
lesion
punctat
abnorm
baselin
low
tendenc
lesion
progress
wherea
particip
earli
confluent
nine
confluent
lesion
underw
median
increas
cm
iqr
cm
respect
lesion
volum
year
lesion
grade
baselin
signific
predictor
lesion
progress
p
punctat
white
matter
lesion
progress
thu
benign
wherea
earli
confluent
confluent
white
matter
abnorm
progress
thu
malign
degre
cerebr
white
matter
chang
almost
endem
elderli
peopl
lesion
progress
individu
unclear
extrem
end
spectrum
fullblown
dementia
correspond
diffus
demyelin
arteriolosclerosi
aim
assess
volum
chang
white
matter
lesion
year
communitydwel
cohort
randomli
select
individu
age
year
without
neuropsychiatr
diseas
commun
regist
studi
particip
underw
brain
mri
baselin
followup
examin
done
year
year
sampl
procedur
clinic
assess
describ
comparison
antivir
potenti
ribavirin
glycyrrhizin
sever
pathogen
flavivirus
cranc
collegu
show
ribavirin
activ
select
inhibitor
assess
regard
inhibit
cell
growth
glycyrrhizin
low
select
index
significantli
potent
inhibitor
replic
virus
test
ec
report
author
glycyrrhizin
mgl
ad
twice
incub
period
day
take
consider
compound
ad
twice
total
period
incub
ec
glycyrrhizin
record
tabl
indic
higher
sensit
sarscv
drug
record
cranc
colleagu
mechan
glycyrrhizin
activ
sarscv
unclear
glycyrrhizin
affect
cellular
signal
pathway
protein
kinas
c
casein
kinas
ii
transcript
factor
activ
protein
nuclear
factor
b
furthermor
glycyrrhizin
aglycon
metabolit
glycyrrhetin
acid
upregul
express
induc
nitrou
oxid
synthas
product
nitrou
oxid
macrophag
nitrou
oxid
inhibit
replic
sever
viruseseg
japanes
enceph
viru
member
flavivirida
famili
also
inhibit
glycyrrhizin
preliminari
result
show
glycyrrhizin
induc
nitrou
oxid
synthas
vero
cell
viru
replic
inhibit
nitrou
oxid
donor
deta
nonoat
ad
cultur
medium
glycyrrhizin
previous
use
treat
patient
chronic
hepat
c
viru
result
low
concentr
antigen
patient
given
compound
attribut
upregul
chemokin
infrequ
sideeffect
rais
blood
pressur
hypokalaemia
report
patient
sever
month
glycyrrhizin
treatment
treatment
sar
need
short
time
sinc
sideeffect
compound
known
control
proper
monitor
could
lead
effect
use
glycyrrhizin
treatment
sar
booth
colleagu
report
ribavirin
mani
toxic
effect
given
patient
sar
includ
haemolysi
patient
drastic
reduct
haemoglobin
patient
howev
although
high
dose
glycyrrhizin
use
clinic
trial
compound
toxic
effect
compar
regimen
drug
report
clinic
effect
futur
search
compound
therapeut
interest
sar
greatli
facilit
establish
growth
sarscv
human
cell
